Welcome to our dedicated page for Gritstone bio news (Ticker: GRTS), a resource for investors and traders seeking the latest updates and insights on Gritstone bio stock.
Gritstone bio, Inc. (Nasdaq: GRTS) is at the forefront of developing personalized cancer immunotherapies and next-generation vaccines for infectious diseases. Headquartered in Emeryville, California, with additional key functions in Cambridge, Massachusetts, Gritstone is a clinical-stage biotechnology company leveraging innovative vectors and payloads to train the immune system to combat critical disease targets. Founded in 2015 with a strong financial backing of $102 million in Series A financing, Gritstone brings together a distinguished team of scientific founders, an experienced management team, and a successful board of directors.
Gritstone's pipeline includes multiple product candidates targeting solid tumors and viral diseases. Their key programs include GRANITE, a personalized neoantigen vaccine program, and SLATE, an 'off-the-shelf' neoantigen vaccine program. Additionally, they are developing CORAL, a next-generation SARS-CoV-2 vaccine designed to drive both B cell and T cell immunity using self-amplifying mRNA (samRNA). Gritstone's collaboration with the National Cancer Institute (NCI) and other industry leaders underscores the pioneering vision and scientific rigor that guides their innovative approaches.
Recent clinical updates have highlighted promising preliminary Phase 2 data for GRANITE in metastatic colorectal cancer (MSS-CRC), showing a progression-free survival benefit. SLATE-KRAS, a variant of their 'off-the-shelf' neoantigen vaccine, has also demonstrated superior immunogenicity in Phase 2 studies. Additionally, their CORAL program continues to show robust and durable immune responses in diverse populations, including those living with HIV.
Gritstone's financial condition remains strong, bolstered by recent public offerings and continued support from prominent foundations and government agencies. Their latest corporate developments and financial results reflect a clear trajectory towards advancing their clinical programs and achieving regulatory milestones.
Gritstone bio (GRTS) presented 6-month follow-up data from its Phase 1 CORAL-CEPI and CORAL-BOOST studies on self-amplifying mRNA (samRNA) vaccine candidates against SARS-CoV-2 at the ECCMID 2023. The results indicate that the samRNA vaccine effectively induces robust neutralizing antibody (nAb) responses that persist for at least 6 months in both vaccine-naïve and previously vaccinated individuals. Key highlights include strong nAb levels with the GRT-R914 and GRT-R910 candidates across diverse populations, including older adults. Both vaccines demonstrated favorable tolerability and the potential for long-term immunity against variants. The findings support the hypothesis that samRNA may serve as a next-generation vaccine platform.
Gritstone bio presented key findings at the 2023 AACR Annual Meeting in Orlando, focusing on its neoantigen vaccine programs, including the GRANITE trial for microsatellite-stable colorectal cancer (MSS-CRC) now in Phase 2/3. The study demonstrated vaccine-elicited T cell responses that may convert 'cold' tumors into 'hot' ones, enhancing treatment efficacy. Gritstone's EDGE™ platform, which predicts neoantigens, showed advancements in identifying class II HLA-presented neoantigens to boost CD4+ T cell responses. Notably, a KRAS G12C epitope was linked to positive clinical benefits. The company anticipates preliminary data from GRANITE by Q4 2023, showcasing the potential of personalized immunotherapies.
Gritstone bio, Inc. (Nasdaq: GRTS) has granted nonqualified stock options to a new employee for 20,000 shares at an exercise price of $2.76, equating to the stock's closing price on April 3, 2023. This grant is in compliance with Nasdaq Listing Rule 5635(c)(4) and is an inducement material to hiring the new employee. The options will vest over four years, with 25% vesting on the first anniversary of employment and the remainder vesting monthly, contingent on continued employment. Gritstone bio is focused on developing potent vaccines to advance treatments for viral diseases and solid tumors, leveraging innovative technology to improve patient outcomes.
Gritstone bio, Inc. (Nasdaq: GRTS) announced presentations at the 33rd ECCMID 2023 in Copenhagen, showcasing their self-amplifying mRNA (samRNA) vaccine candidates. The presentations will detail the CORAL program's efforts in fighting COVID-19, particularly with candidates targeting the virus's Spike protein. Key sessions include a poster presentation on samRNA vaccines in HIV-positive and healthy adults and an ePoster session on the GRT-R910 vaccine's immunogenicity in older volunteers. These studies aim to validate Gritstone’s innovative approach to infectious diseases.
Gritstone bio, Inc. (GRTS) announced multiple presentations at the 2023 AACR Annual Meeting, highlighting its innovative neoantigen vaccine programs. Key presentations include a poster on peptide-HLA interactions and a minisymposium discussing disease monitoring through genomics. The company detailed its proprietary EDGE™ neoantigen prediction capabilities and the progress of its GRANITE program, which is in a Phase 2/3 study for colorectal cancer. Gritstone emphasizes its commitment to developing potent vaccines targeting critical diseases, leveraging advanced technologies.
FAQ
What is the current stock price of Gritstone bio (GRTS)?
What is the market cap of Gritstone bio (GRTS)?
What does Gritstone bio, Inc. specialize in?
Where is Gritstone bio, Inc. headquartered?
What are Gritstone's key product candidates?
What recent clinical updates has Gritstone reported?
Who are Gritstone bio's collaborators?
When was Gritstone bio founded, and how was it funded?
What makes Gritstone's vaccines unique?
How does Gritstone's financial condition look?
What is the significance of the CORAL program?
What is the future outlook for Gritstone bio?
